NR1H4 and primary biliary cholangitis: 1999; Chiang 2009) as illustrated in Figure 6. Identification of FXR as a therapeutic target for the treatment of chronic liver diseases (e.g., PBC) has led to the development of more potent FXR agonists including OCA (Ali et al. 2015).